Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
There are limited treatment options for patients with unresectable hepatocellular carcinoma
(HCC) who failed to the combination therapy with targeted agents plus anti-PD-1/PD-L1.
Hepatic artery infusion chemotherapy (HAIC) had shown potent antitumor effects in
single-centered studies when was used as first-line therapy. However, HAIC was not used as
second or third-line therapy.